Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on May 09, 2022 10:31am
96 Views
Post# 34666677

RE:RE: 1 share traded

RE:RE: 1 share traded..and the wide spread of 10cents shows there is a high degree of uncertainty so both seller and buyer need to be enticed at either end instead of a liquid market with a lot of depth creating a very tight spread so you can transact.  It's all about lack of information with a dwindling and very small audience.  Once again, the upside to it would be IF there is positive info, it will work the opposite way.  Maybe they can attract an audience, transactions go up, spreads diminish, share rises. But they need something positive first.   

Seems we'll get dosage, safety info in brief form, a possible conferece poster later, and a larger push in to the basket trial.  But they should at a minimum lay out to the investors what the plan now looks like, what the regulatory strategy is, the PPD/Clinic recruiting strategy is, etc...  There's just still so much they could educate the market about but sounds like they could care less about doing so if they just release "We hit MTD and will use 300mg as RP2D.  No SAEs there.  On to basket trial. More later."   That would be a bigtime mistake.  Start building the audience now.  Forget about saving things for a conference to win personal accolades.  We're talking the fair valuation of your company here, not scoring points in the oncology egghead world.

SPCEO1 wrote: Sad and incomprehensible.

SS1316 wrote: I'm showing That as of 10:12 am EST only 1 share has been traded... sad




<< Previous
Bullboard Posts
Next >>